a Phase 2/3 clinical study of its developmental DNA coronavirus vaccine. ” data-reactid=”19″>Inovio Pharmaceuticals Inc (NASDAQ: INO) failed to inspire confidence among investors despite revealing in its second-quarter earnings report that it is on track for a September start for a Phase 2/3 clinical study of its developmental DNA coronavirus vaccine.
Charles Duncan reiterated an Overweight rating on Inovio shares and reduced the price target from $45 to $31. ” data-reactid=”20″>The Inovio Analyst: Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Inovio shares and reduced the price target from $45 to $31.
here.)” data-reactid=”21″>The Inovio Thesis: Inovio’s planned Phase 3 study in at-risk volunteers with an assumed higher case rate — although encouraging — poses greater execution risk and mounting competition for clinical trial resources and in-market demand, given the progress made by other vaccine developers, Duncan said in a Tuesday note. (See his track record here.)
Cantor is taking a conservative stance and reduced its estimate for Inovio’s number of doses sold in 2022-2026, the analyst said.
Given Inovio’s quarter-end cash position of $372 million, there is likely to be sufficient funding into 2023, with a bevy of potential pipeline milestones, he said.
Phase 1 study and qualitative characterization of the composition of immune responses warrant movement of the investigational vaccine into a Phase 2/3 efficacy study, Duncan said. ” data-reactid=”28″>The 94% responder rate for the INO-4800 vaccine in the Phase 1 study and qualitative characterization of the composition of immune responses warrant movement of the investigational vaccine into a Phase 2/3 efficacy study, Duncan said.
The analyst said he expects patient enrollment in the study to occur during the summer or early fall.
View more earnings on INO” data-reactid=”30″>View more earnings on INO
The proposed Phase 2/3 study is likely to enroll health care workers, first responders and persons in other occupations that place them at higher risk of COVID-19 infection, he said.
The size and the speed of the study will depend on several factors, including the viral attack rate, Duncan said.
The company is also expected to release 18-month overall survival data from INO-5401/INO-9012/checkpoint inhibitor in glioblastoma multiforme and data from the Phase 2 study of MEDI-0457 in combination with durvalumab for metastatic HPV-related squamous cell carcinoma of the head and neck, according to Cantor Fitzgerald.
Latest Ratings for INO
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 2020 | Maxim Group | Downgrades | Buy | Hold |
| Jun 2020 | HC Wainwright & Co. | Downgrades | Buy | Neutral |
| Jun 2020 | Cantor Fitzgerald | Maintains | Overweight |
View Article Origin Here
